Pathogenetic Mechanisms and Clinical Manifestations of Diabetic Peripheral Polyneuropathy in Type 2 Diabetes Mellitus Xaydarova Xilolaxon Ravshan qizi, Xolmatova Gulxayo Azimjonovna-

Авторы

  • Xilolaxon Ravshan qizi Xaydarova Andijan State Medical Institute image/svg+xml Автор
  • Gulxayo Azimjonovna Xolmatova Andijan State Medical Institute (Associate Professor, PhD in Medical Sciences, Department of Hospital Therapy and Endocrinology) Автор

Ключевые слова:

Type 2 diabetes mellitus, diabetic peripheral neuropathy, pathogenesis, oxidative stress, inflammation, microvascular dysfunction, neuropathic pain, treatment

Аннотация

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that has become one of the leading global health challenges due to its rapidly increasing prevalence and numerous long-term complications. Among these complications, diabetic peripheral polyneuropathy (DPN) is the most common neurological disorder, affecting approximately one-third to one-half of patients with diabetes. DPN is characterized by progressive degeneration of peripheral nerves resulting from complex metabolic, vascular, inflammatory, and neurodegenerative processes initiated by persistent hyperglycemia. The pathogenesis of diabetic peripheral polyneuropathy involves multiple interconnected mechanisms, including activation of the polyol pathway, excessive formation of advanced glycation end products, oxidative stress, mitochondrial dysfunction, chronic inflammation, endothelial impairment, and microvascular ischemia. These pathological changes ultimately lead to axonal degeneration, segmental demyelination, impaired nerve conduction, and irreversible neuronal damage. Clinically, diabetic peripheral polyneuropathy presents with distal symmetric sensory loss, paresthesia, burning pain, numbness, muscle weakness, impaired proprioception, and reduced tendon reflexes. Disease progression significantly increases the risk of diabetic foot syndrome, recurrent ulceration, infection, lower-limb amputation, and reduced quality of life. Early diagnosis using neurological examination, quantitative sensory testing, nerve conduction studies, and validated clinical scoring systems remains crucial for preventing irreversible complications. Current treatment strategies combine strict glycemic control with pathogenetic therapies, antioxidant agents, symptomatic pain management, lifestyle modification, and comprehensive foot care. Emerging therapeutic approaches targeting oxidative stress, neuroinflammation, mitochondrial dysfunction, and nerve regeneration offer promising opportunities for improving long-term outcomes. This review summarizes current knowledge regarding the epidemiology, pathogenetic mechanisms, clinical manifestations, diagnostic approaches, and modern therapeutic strategies for diabetic peripheral polyneuropathy associated with type 2 diabetes mellitus.

Indeks havolalari

Google Scholar Zenodo OpenAIRE BASE OpenAlex Semantic Scholar DataCite

Опубликован

2026-11-11

Выпуск

Раздел

Articles

Как цитировать

Pathogenetic Mechanisms and Clinical Manifestations of Diabetic Peripheral Polyneuropathy in Type 2 Diabetes Mellitus Xaydarova Xilolaxon Ravshan qizi, Xolmatova Gulxayo Azimjonovna-. (2026). Tibbiyot, 11, 22-37. https://reandpub.uz/tibbiyot/article/view/1523

Библиографические ссылки

Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nature Reviews Endocrinology. 2021;17(7):400–420.

Yang Y, Zhao B, Wang Y, Lan H, Liu X, Hu Y, et al. Diabetic neuropathy: cutting-edge research and future directions. Signal Transduction and Targeted Therapy. 2025;10:132.

Savelieff MG, Elafros MA, Viswanathan V, Jensen TS, Bennett DL, Feldman EL, et al. The global and regional burden of diabetic peripheral neuropathy. Nature Reviews Neurology. 2025;21(1):17–31.

Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabetic neuropathy. Nature Reviews Disease Primers. 2019;5:41.

Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154.

American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl. 1):S1–S350.

International Diabetes Federation. IDF Diabetes Atlas. 11th ed. Brussels, Belgium: International Diabetes Federation; 2025.

Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293.

Calcutt NA. Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms? Pain. 2020;161(Suppl 1):S65–S86.

Ziegler D. Pathogenetic treatments for diabetic peripheral neuropathy. Diabetes Research and Clinical Practice. 2023;206:110764.